Lessons From a Rare Randomized Controlled Trial of Immunosuppressant Management After Kidney Transplantation
- PMID: 37749787
- DOI: 10.1097/TP.0000000000004819
Lessons From a Rare Randomized Controlled Trial of Immunosuppressant Management After Kidney Transplantation
Comment on
-
Comparison of 2 Immunosuppression Minimization Strategies in Kidney Transplantation: The ALLEGRO Trial.Transplantation. 2024 Feb 1;108(2):556-566. doi: 10.1097/TP.0000000000004776. Epub 2024 Jan 19. Transplantation. 2024. PMID: 37650722 Clinical Trial.
References
-
- Joost C, van den Born JC, Meziyerh S, et al. Comparison of 2 immunosuppression minimization strategies in kidney transplantation: the Amsterdam-LEiden-GROningen Randomized Controlled (ALLEGRO) Trial. Transplantation. 2024;108:556–566.
-
- Tong A, Gill J, Budde K, et al.; SONG-Tx Investigators. Toward establishing core outcome domains for trials in kidney transplantation: report of the standardized outcomes in nephrology-kidney transplantation consensus workshops. Transplantation. 2017;101:1887–1896.
-
- Mayer KA, Doberer K, Halloran PF, et al. Anti-interleukin-6 antibody clazakizumab in antibody-mediated kidney transplant rejection: effect on donor-derived cell-free DNA and C-X-C motif chemokine ligand 10. Transplant Direct. 2022;8:e1406.
-
- Collins MG, Fahim MA, Pascoe EM, et al.; BEST-Fluids Investigators. Balanced crystalloid solution versus saline in deceased donor kidney transplantation (BEST-Fluids): a pragmatic, double-blind, randomised, controlled trial. Lancet. 2023;402:105–117.
-
- Graver AS, Lee D, Power DA, et al. Understanding donor-derived cell-free DNA in kidney transplantation: an overview and case-based guide for clinicians. Transplantation. 2023;107:1675–1686.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
